SCHEMBL3484473

SCHEMBL3484473

COc1ccc(C(=O)Nc2sc(-c3ccccc3)cc2C(N)=O)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.76
ALDH1A1 P00352 3/20 0.73
GAA P10253 2/20 0.73
HPGD P15428 2/20 0.73
CYP1A2 P05177 1/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
CHEK1 O14757 2/20 0.70
MAPT P10636 3/20 0.65
RAB9A P51151 2/20 0.65
KDM4E B2RXH2 2/20 0.65
MEN1 O00255 1/20 0.65
POLB P06746 1/20 0.65
KMT2A Q03164 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
IKBKB O14920 1/20 0.63
JAK2 O60674 1/20 0.63
JAK3 P52333 1/20 0.63
NPC1 O15118 1/20 0.62
PTPN5 P54829 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7006938 0.90 KDR (0.65) KDRALDH1A1GAAHPGDCYP1A2
SCHEMBL17318563 0.86 KDR (1.00) KDRALDH1A1GAAHPGDCYP1A2
SCHEMBL7004367 0.84 KDR (0.70) KDRMAPTRAB9AIKBKBJAK2
SCHEMBL17318541 0.83 KDR (0.69) KDRMAPTRAB9AIKBKBJAK2
SCHEMBL4089013 0.83 CHEK1 (1.00) CHEK1MEN1KMT2AIKBKBJAK2
SCHEMBL7003324 0.82 IKBKB (0.64) KDRALDH1A1GAAHPGDCHEK1
SCHEMBL5898652 0.82 CHEK1 (0.83) ALDH1A1GAAHPGDCHEK1MAPT
SCHEMBL24488930 0.81 ALDH1A1 (0.74) KDRALDH1A1GAAHPGDCYP1A2
SCHEMBL7003892 0.81 KDR (0.62) KDRALDH1A1GAAHPGDMAPT
SCHEMBL7055920 0.80 CHEK1 (0.79) CHEK1MEN1KMT2AIKBKBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6414013-B1 KINASE INHIBITORS; ANTICANCER AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-07-02 US claimed
US-8263642-B2 Antimicrobial compounds and methods of use thereof VANDERBILT UNIVERSITY (US) 2012-09-11 US disclosed
US-8263642-B2 Antimicrobial compounds and methods of use thereof VANDERBILT UNIVERSITY (US) 2012-09-11 US disclosed
US-8263642-B2 Antimicrobial compounds and methods of use thereof VANDERBILT UNIVERSITY (US) 2012-09-11 US disclosed
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF VANDERBILT UNIVERSITY 2010-01-07 US disclosed
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF VANDERBILT UNIVERSITY 2010-01-07 US disclosed
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF VANDERBILT UNIVERSITY 2010-01-07 US disclosed
US-6414013-B1 KINASE INHIBITORS; ANTICANCER AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004324-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF HMOX1, HMOX2, NOD2 KDR 4419/4885ALDH1A1 4316/4885GAA 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.